Skip to content

ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions

Contrast-Induced Acute Kidney Injury

The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and/or percutaneous coronary intervention (PCI).

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Age ≥18 years;
* Planned coronary angiogram and/or PCI;
* Willingness to participate and to attend study visits;
* Expected life expectancy ≥6 months.

Exclusion Criteria:

* Cardiogenic or non-cardiogenic shock at the time of the procedure;
* Emergent procedures (e.g. STEMI);
* Iodine-based contrast media received within 2 days;
* Presence of Intra-Aortic Balloon Pump (IABP);
* Cardiac arrest within 24 hours;
* Pre-procedural AKI defined using the modified KDIGO criteria within 7 days;
* Renal replacement therapy;
* Severe aortic or mitral disease;
* LVEF \<30%.

Lieu de l'étude

Montreal Heart Institute
Montreal Heart Institute
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Guillaume Marquis-Gravel, MD, MSc

[email protected]
9195193271
Étude parrainée par
Montreal Heart Institute
Participants recherchés
Plus d'informations
ID de l'étude: NCT04936607